{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:19:28Z","timestamp":1770815968003,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.bone.2011.09.035","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T21:05:28Z","timestamp":1316207128000},"page":"1317-1322","source":"Crossref","is-referenced-by-count":24,"title":["Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease \u2014 The DIVINE study"],"prefix":"10.1016","volume":"49","author":[{"given":"Paul","family":"D. Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ragi-Eis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mautalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Jonkanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.09.035_bb0005","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2011.09.035_bb0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14740338.6.6.663","article-title":"Renal safety of intravenous bisphosphonates in the treatment of osteoporosis","volume":"6","author":"Lewiecki","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bone.2011.09.035_bb0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2165\/00002018-200629120-00005","article-title":"Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease","volume":"29","author":"Bobba","year":"2006","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.bone.2011.09.035_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","volume":"49","author":"Miller","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.09.035_bb0025","first-page":"18","article-title":"Pharmacokinetics of alendronate: an overview","volume":"101","author":"Lin","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.bone.2011.09.035_bb0030","unstructured":"US Food and Drug Administration. Adverse Event Reporting Systems (AERS): Healthcare Professionals. The Drug Safety Newsletter. In: Vol 2; No 2.; 2009."},{"key":"10.1016\/j.bone.2011.09.035_bb0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.09.035_bb0040","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.09.035_bb0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.09.035_bb0050","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bone.2011.09.035_bb0055","first-page":"1125","article-title":"Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review","volume":"26","author":"Miller","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.bone.2011.09.035_bb0060","first-page":"S212","article-title":"Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from Diva [abstract P316SA]","volume":"17","author":"Eisman","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.09.035_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2011.09.035_bb0110","series-title":"Frequently asked questions about GFR estimates","author":"Stevens","year":"2007"},{"key":"10.1016\/j.bone.2011.09.035_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2011.09.035_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.bone.2011.09.035_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2011.09.035_bb0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1185\/030079904125003548","article-title":"Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study","volume":"20","author":"Eisman","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"Suppl II","key":"10.1016\/j.bone.2011.09.035_bb0115","first-page":"404","article-title":"Continued favourable renal tolerability with ibandronate intravenous injections in women with postmenopausal osteoporosis: The DIVA study LTE","volume":"67","author":"Czerwinski","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bone.2011.09.035_bb0100","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1016\/j.jocd.2007.03.074","article-title":"A pooled analysis demonstrates IV ibandronate injection is associated with a favorable renal safety profile","volume":"10","author":"Miller","year":"2007","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.bone.2011.09.035_bb0120","series-title":"Boniva (ibandronate sodium) US prescribing information","author":"Genentech","year":"2010"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211012361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211012361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T02:24:27Z","timestamp":1543544667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211012361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S8756328211012361"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.09.035","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}